Shelly T. Karuna

Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division

Seattle, WA 98109-1024

United States

SCHOLARLY PAPERS

5

DOWNLOADS

211

TOTAL CITATIONS

0

Scholarly Papers (5)

1.

Lower SARS-CoV-2-Specific Humoral Immunity in People Living With HIV-1 Recovered From Symptomatic Non-Hospitalized COVID-19

Number of pages: 44 Posted: 04 Jan 2022
affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - School of Medicine, affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University, affiliation not provided to SSRN, Duke University - Duke Human Vaccine Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Pennsylvania - Department of Medicine, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology and affiliation not provided to SSRN
Downloads 64 (705,067)

Abstract:

Loading...

HIV-1, PLWH, People Living with HIV, SARS-CoV-2, COVID-19, humoral immunity, antibody, antibody isotype, antibody subclass, ACE-2 blocking, ADCP, antibody dependent phagocytosis, Multiplex assay, Meso Scale Discovery, IgG, IgG1, IgG3, IgA, CoVPN

2.

Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition

Number of pages: 35 Posted: 18 Oct 2022
Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University, Duke University - School of Medicine, Duke University - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Independent, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington, University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington - Department of Biostatistics, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Family Health International, Via Libre CRS, University of California, Los Angeles (UCLA) - Department of Medicine, Wits Health Consortium - Perinatal HIV Research Unit (PHRU), University of Cape Town (UCT) - Department of Medicine, University of Pennsylvania, Asociacion Civil Impacta Salud y Educacion, Emory University - School of Medicine, San Miguel Clinical Research Center - Asociacion Civil Impacta Salud y Educacion, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, National Institute for Communicable Diseases of the National Health Laboratory Service, Duke University - Duke Human Vaccine Institute, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division and Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology
Downloads 56 (751,530)

Abstract:

Loading...

body weight, HIV, prevention, broadly neutralizing antibodies, monoclonal antibody, pharmacokinetics

3.

Infusion Reactions in Persons Receiving the Broadly Neutralizing Antibody VRC01 or Placebo for Reduction of HIV-1 Acquisition: Results From the Phase 2b Antibody Mediated Prevention (AMP) Randomized Trials

Number of pages: 30 Posted: 14 May 2021
Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Emory University - School of Medicine, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, National Institutes of Health - Vaccine Research Center, Botswana Harvard AIDS Institute Partnership (BHP), University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, South African Medical Research Council, Asociacion Civil Impacta Salud y Educacion, Oswaldo Cruz Foundation (FIOCRUZ) - Instituto Nacional de Infectologia Evandro Chagas (INIEC), Harvard University - Brigham and Women’s Hospital, Family Health International, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center, Aurum Institute and University of Zimbabwe - Clinical Trials Research Centre
Downloads 37 (891,983)

Abstract:

Loading...

infusion related reactions, hypersensitivity, broadly neutralizing antibodies, AMP study, HIV

4.

Fixed Dosing Versus Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults: A Pharmacokinetics Modeling Study

Number of pages: 23 Posted: 14 Jan 2025
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Family Health International, HPTN Leadership and Operations Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Fred Hutchinson Cancer Research Center, Harvard University - Brigham and Women’s Hospital, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Kelly Government Solutions, Columbia University - Aaron Diamond AIDS Research Center, Columbia University - Irving Medical Center, Emory University - School of Medicine, University of North Carolina (UNC) at Chapel Hill, Harvard University - Beth Israel Deaconess Medical Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Emory University - Division of Infectious Diseases, University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa (CAPRISA), George Washington University - School of Medicine and Health Sciences, National Institutes of Health, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, National Institutes of Health - Vaccine Research Center and Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology
Downloads 35 (909,973)

Abstract:

Loading...

HIV prevention, dosing strategy, exponent of body weight, two-compartment, population pharmacokinetics model, variability in exposure

5.

The Brighton Collaboration Standardized Module for Mpox Vaccines, Mva-Bn and Lc16m8, Benefit-Risk Assessment

Number of pages: 90 Posted: 30 Jan 2025
University of Washington, affiliation not provided to SSRN, CEPI, affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division and affiliation not provided to SSRN
Downloads 19 (1,104,893)

Abstract:

Loading...

Benefit-risk, mpox vaccines, MVA-BN, LC16m8, module, vaccine safety, Vaccines, guidelines, adults, immunocompromised